All News
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read Article
#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC
Mrinalini Dey DrMiniDey ( View Tweet)
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated.
Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
Bella Mehta bella_mehta ( View Tweet)
Sarcoidosis increases the risk of MGUS and multiple myeloma. Propensity matched Data from a large global collaborative network study with 40k pts.
POS0231 #EULAR2026 @RheumNow https://t.co/mygYCjigFV
Bella Mehta bella_mehta ( View Tweet)
#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA?
Yes: faster remission at week 4 (84.6% vs 15%)
But: equal at week 24
Prospective study in 46 patients
#POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Top tips:
⭐️ Summarise the key facts but always provide the source
⭐️ Learn from mistakes to improve what you have
⭐️ Have high quality source material- scan multiple resources for the best quality info and latest news!
@RheumNow
#EULAR2026
Mrinalini Dey DrMiniDey ( View Tweet)
What makes a good rheum learning platform?
@rheumnow’s Dr Jack Cush gives a masterclass in online learning and medical education, including the background to RheumNow.
#EULAR2026 @EMEUNET https://t.co/2cXpRXPK13
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
What do you think about this cartoon-style format for posters?
A- I love it!
B- It’s Ok but I prefer classic
As for the content: Axia digital therapeutic app improves mobility, BASDAI, sleep an sexual function in 32 patients
#POS0199 #EULAR2026 @rheumnow https://t.co/mV83dMF4vi
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
Dr. John Cush RheumNow ( View Tweet)
#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB
TheDaoIndex KDAO2011 ( View Tweet)
Which imaging test has the highest carbon footprint???
Think wisely before prescribing 🩻
#EULAR2026
@RheumNow https://t.co/36Ej8smWRd
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Did you take part in #RheumaVision this year?
@cristianasieiro takes us through the past, present & future of this innovative initiative, which held its final yesterday at #EULAR2026.
You can watch all the videos online- and be sure to participate next year!
@EMEUNET
@RheumNow https://t.co/liWzYYbIxI
Mrinalini Dey DrMiniDey ( View Tweet)
🩺🌳When good clinical practice meets reducing environmental burden of healthcare:
Rheumatologists can do a lot!
Less is more ⬇️
Thank you @eular_org for planning environmental awareness sessions
Looking forward to #greener congresses
#EULAR2026
@RheumNow https://t.co/5FwARRi92m
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#RheumMadness comes to #EULAR2026!
Dr David Leverenz takes us through the background and process of this firm favourite in rheum education. An excellent example of gamification for medical education more broadly.
@RheumNow https://t.co/lmgkJbTgBm
Mrinalini Dey DrMiniDey ( View Tweet)
Another reason for NOT prescribing ANA (and other tests) as a “screening” test when not indicated:
High carbon footprint!
#EULAR2026
@rheumnow https://t.co/BAuzQuZ0Iv
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0340 WK84 data of single arm Phase 2 Daratumumab (CD38 plasma depleter) weekly for 8 doses with background IS in N=10 #SLE: rapid reduction of antidsDNA & efficacy. 6/10 relapsed from WK20; 5/10 had low IgG and needed IVIG. Promising but Not so durable @RheumNow https://t.co/UrTywqkQ4F
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What does remission look like for people living with PsA?
Much more than the absence of swollen joints
Absence of pain
Skin management
Ability to resume daily activities
Sustained over time
A definition not always reflected in our disease activity scores
#POS0294 #EULAR2026 https://t.co/VCnMGAOVYm
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
